Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1386 crossover study of esophageal sensitivity in GERD partial responders to PPI
2008-007420-26Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD-1386 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Esophageal sensitivity to thermal stimuli at 1.5 hours post-dose. Started Mar 2009; status: terminated.
02
Drugs
AZD-1386
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2008-007420-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007420-26.